Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
💎 Reveal Undervalued Stocks Hiding in Any Market Get Started
QuickView: Mesoblast
www.investing.com/analysis/quickview:-mesoblast-160250
QuickView: Mesoblast
By Edison | Mar 24, 2013 07:28AM ET
Mesoblast’s (MSB.AX) current valuation assumes a high probability of success for its stem cell technology, but it does hold the leadership position in this field. A proposed large Phase III study of Revascor in congestive heart failure (CHF), which is to be fully funded by co-development partner Teva, holds promise of both validating the company’s mesenchymal precursor cell (MPC) platform and moving stem cell therapeutics closer to commercial reality in the US. However, an EV of A$1.59bn, when compared to peers, belies the risk of any clinical trial setbacks and potential competition from rival approaches to indications being targeted.
Revascor to enter Phase III in congestive heart failure
A planned Phase III trial of lead product Revascor in 1,700 patients with CHF should start in 2013, with co-development partner Teva bearing all costs. Early data is positive but limited. A 60-patient Phase II trial examining the safety and efficacy of three doses of Revascor showed patients treated with a single intra-cardiac injection of the highest dose had no hospitalisation events for decompensated heart failure or cardiac-related deaths, over a mean follow-up period approaching three years.
Stem cell therapy - promising but risky
Despite the potential of engineered stem cell therapies to address major unmet needs, the technology is unproven and there remains considerable clinical and regulatory risk. The FDA is yet to approve such a treatment.
Multiple clinical programmes - single technology platform
The recent A$170m capital raising extends the cash runway for funding of multiple clinical programmes (six Phase II, five preclinical) through to 2016, based on its current US$65m pa burn rate, during which time clinical data should be reported. In addition to cardiovascular indications, clinical trials are also targeting degenerative disc disease, type-2 diabetes and wet age-related macular degeneration (AMD). Although this portfolio approach provides multiple shots at goal, clinical risk inherent in each trial is compounded overall by the use of a single technology platform.
Valuation: Assumes high probability of clinical success
An EV of A$1.59bn, based on net cash of A$332m (March 2013, including A$170m raising), assumes a high probability of success across a development pipeline built on a single technology platform with limited clinical efficacy data to date. By comparison, Osiris, which has the, albeit niche, allogenic stem cell therapy Prochymal (remestemcel-L) approved in Canada in 2012, has an EV of US$338m.
To Read the Entire Report Please Click on the pdf File Below.
Revascor to enter Phase III in congestive heart failure
A planned Phase III trial of lead product Revascor in 1,700 patients with CHF should start in 2013, with co-development partner Teva bearing all costs. Early data is positive but limited. A 60-patient Phase II trial examining the safety and efficacy of three doses of Revascor showed patients treated with a single intra-cardiac injection of the highest dose had no hospitalisation events for decompensated heart failure or cardiac-related deaths, over a mean follow-up period approaching three years.
Stem cell therapy - promising but risky
Despite the potential of engineered stem cell therapies to address major unmet needs, the technology is unproven and there remains considerable clinical and regulatory risk. The FDA is yet to approve such a treatment.
Multiple clinical programmes - single technology platform
The recent A$170m capital raising extends the cash runway for funding of multiple clinical programmes (six Phase II, five preclinical) through to 2016, based on its current US$65m pa burn rate, during which time clinical data should be reported. In addition to cardiovascular indications, clinical trials are also targeting degenerative disc disease, type-2 diabetes and wet age-related macular degeneration (AMD). Although this portfolio approach provides multiple shots at goal, clinical risk inherent in each trial is compounded overall by the use of a single technology platform.
Valuation: Assumes high probability of clinical success
An EV of A$1.59bn, based on net cash of A$332m (March 2013, including A$170m raising), assumes a high probability of success across a development pipeline built on a single technology platform with limited clinical efficacy data to date. By comparison, Osiris, which has the, albeit niche, allogenic stem cell therapy Prochymal (remestemcel-L) approved in Canada in 2012, has an EV of US$338m.
To Read the Entire Report Please Click on the pdf File Below.
Related Articles
Deutsche Bank in Trouble: Will the German Giant, Too, Turn Belly Up?
By Damian Nowiszewski/Investing.com - Mar 27, 2023
Last week, Deutsche Bank's stock plunged, and CDS rose, causing concern among investors and depositors. The long-standing structural problems at Deutsche Bank, dating back to the...
Financial Sector Teetering on Historic Technical Support
By Chris Kimble - Mar 27, 2023
The financial sector is the focal point of the global economy. So it’s no wonder that investors pay close attention to its performance within the stock market. And this is...
Semiconductors on Verge of Breakout as Russell 2000 Holds Strong
By Declan Fallon - Mar 27, 2023
"Hope" is a bad word in trading, but markets are holding up better than I expected. The Russell 2000 is the index to watch because of the import of growth stocks to secular bull...
QuickView: Mesoblast
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.